Hospital
State of Mississippi-University of Mississippi Medical Center
State of Mississippi-University of Mississippi Medical Center was paid $17.82M by Medicaid between Jan 2018 and Dec 2024, across 261 billing codes. Its largest line is 99283, emergency room visit (moderate) — 13% of everything it billed.
33Billing provider infoSTATE OF MISSISSIPPI-UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
GRENADA, MS 38901
GRENADA, MS 38901
33aNPI1558798603assigned 10/03/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.82M
24GClaims615,000
24DCodes billed261
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#26 of 77
Median peer was paid$8.23M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 85,118 | $2.66M | |
| 2019 | 80,520 | $2.73M | |
| 2020 | 73,134 | $2.15M | |
| 2021 | 83,777 | $2.36M | |
| 2022 | 101,109 | $2.59M | |
| 2023 | 108,167 | $2.94M | |
| 2024incomplete | 83,175 | $2.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 19,590 | 16,166 | $2.32M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 13,881 | 11,560 | $2.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 6,124 | 5,050 | $1.14M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 8,835 | 7,069 | $815K |
| G0378 | Hospital observation service, per hour | 3.9% | 3,029 | 2,303 | $692K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 5,774 | 4,984 | $474K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.5% | 10,872 | 9,046 | $453K |
| 86885 | 2.1% | 5,121 | 3,993 | $368K | |
| 71045 | Radiologic examination, chest; single view | 2.0% | 10,810 | 8,862 | $362K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 2,526 | 2,206 | $338K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 8,808 | 7,001 | $338K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 13,492 | 2,456 | $336K |
249 more codes
| 86900 | 1.7% | 5,575 | $295K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.6% | 11,226 | $278K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.5% | 11,234 | $272K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 2,626 | $263K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 6,860 | $257K |
| 81513 | 1.3% | 2,773 | $227K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,500 | $222K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 42,313 | $206K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 3,198 | $189K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 1.0% | 2,624 | $180K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,233 | $177K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,114 | $173K |
| 80053 | Comprehensive metabolic panel | <1% | 24,334 | $159K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,677 | $154K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 11,604 | $148K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 6,992 | $142K |
| 87428 | <1% | 2,665 | $139K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,663 | $139K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,196 | $137K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 833 | $129K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 7,751 | $127K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,692 | $123K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,480 | $118K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,935 | $112K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,399 | $107K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,525 | $104K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,240 | $100K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,122 | $97K |
| 74018 | <1% | 2,425 | $96K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,755 | $95K |
| 86901 | <1% | 5,562 | $91K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 788 | $90K |
| A0425 | Ground mileage, per statute mile | <1% | 1,093 | $88K |
| 80074 | <1% | 2,658 | $82K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 30,589 | $79K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 945 | $70K |
| 80306 | <1% | 6,068 | $70K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,757 | $69K |
| 76801 | <1% | 1,069 | $69K | |
| 87481 | <1% | 3,016 | $68K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,982 | $66K |
| 11043 | <1% | 474 | $64K | |
| 87070 | <1% | 9,004 | $63K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,427 | $62K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,978 | $60K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 807 | $55K |
| 72100 | <1% | 1,135 | $55K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 185 | $51K |
| 83880 | <1% | 2,993 | $50K | |
| 73030 | <1% | 1,457 | $45K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,131 | $44K |
| 84702 | <1% | 4,149 | $44K | |
| 84484 | <1% | 7,562 | $44K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 827 | $42K |
| 73630 | <1% | 1,066 | $41K | |
| 59025 | Fetal non-stress test | <1% | 421 | $38K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,851 | $37K |
| 80061 | Lipid panel | <1% | 4,008 | $36K |
| 81025 | <1% | 6,344 | $36K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,946 | $35K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 160 | $34K |
| 73610 | <1% | 762 | $32K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,173 | $31K |
| 83021 | <1% | 2,353 | $30K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 705 | $30K |
| 76830 | Ultrasound, transvaginal | <1% | 515 | $30K |
| 81001 | <1% | 13,474 | $30K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,949 | $28K |
| 86762 | <1% | 2,715 | $28K | |
| 87077 | <1% | 4,849 | $26K | |
| 73130 | <1% | 634 | $26K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 413 | $26K |
| 87040 | <1% | 4,780 | $25K | |
| 86780 | <1% | 2,861 | $25K | |
| 86787 | <1% | 2,800 | $25K | |
| 87186 | <1% | 4,070 | $24K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,027 | $23K |
| 76642 | <1% | 669 | $23K | |
| 82947 | <1% | 9,848 | $23K | |
| 86696 | <1% | 1,605 | $22K | |
| 87807 | <1% | 1,864 | $20K | |
| 83735 | <1% | 5,980 | $20K | |
| 73502 | <1% | 708 | $18K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,199 | $18K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,001 | $17K |
| 73562 | <1% | 515 | $17K | |
| 86592 | <1% | 5,352 | $17K | |
| 76770 | <1% | 361 | $16K | |
| 59050 | <1% | 475 | $16K | |
| 83690 | <1% | 4,337 | $16K | |
| 86695 | <1% | 1,611 | $15K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 175 | $15K |
| 73560 | <1% | 473 | $14K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 490 | $13K |
| 87660 | <1% | 1,055 | $13K | |
| 87480 | <1% | 1,055 | $13K | |
| 83605 | <1% | 2,667 | $13K | |
| 87510 | <1% | 1,055 | $13K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 142 | $12K |
| 97016 | <1% | 1,955 | $12K | |
| 86140 | <1% | 3,129 | $12K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 522 | $11K |
| 36902 | <1% | 15 | $11K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 150 | $11K |
| 97014 | <1% | 1,289 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 333 | $10K |
| 85027 | <1% | 2,284 | $10K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 84 | $10K |
| 87340 | <1% | 1,203 | $9K | |
| 97161 | <1% | 254 | $9K | |
| 85610 | <1% | 4,131 | $9K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 27 | $9K |
| 84153 | <1% | 989 | $9K | |
| 87081 | <1% | 1,679 | $9K | |
| 85730 | <1% | 2,678 | $9K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 626 | $8K |
| 97162 | <1% | 227 | $8K | |
| 81003 | <1% | 4,958 | $8K | |
| 93925 | <1% | 110 | $8K | |
| 82550 | <1% | 1,926 | $7K | |
| 77066 | Tomosynthesis, mammo | <1% | 105 | $7K |
| 93971 | <1% | 210 | $7K | |
| 81243 | <1% | 1,136 | $7K | |
| 82248 | <1% | 1,801 | $6K | |
| 36430 | <1% | 68 | $6K | |
| 87563 | <1% | 281 | $6K | |
| 87486 | <1% | 185 | $6K | |
| 87581 | <1% | 185 | $6K | |
| 84439 | <1% | 922 | $6K | |
| 86694 | <1% | 516 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 177 | $5K |
| 72040 | <1% | 150 | $5K | |
| 87205 | <1% | 1,540 | $5K | |
| 73564 | <1% | 82 | $5K | |
| 77065 | Tomosynthesis, mammo | <1% | 87 | $5K |
| 85379 | <1% | 872 | $4K | |
| 93970 | <1% | 74 | $4K | |
| 82105 | <1% | 367 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,588 | $4K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 37 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 66 | $4K |
| 71250 | <1% | 108 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 71 | $4K |
| 73110 | <1% | 110 | $4K | |
| 97165 | <1% | 83 | $4K | |
| 76000 | <1% | 50 | $4K | |
| 87536 | <1% | 62 | $3K | |
| 84550 | <1% | 1,203 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,759 | $3K |
| 84703 | <1% | 468 | $3K | |
| 92523 | <1% | 18 | $2K | |
| 85652 | <1% | 1,335 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 20 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 84 | $2K |
| 73590 | <1% | 57 | $2K | |
| 83615 | <1% | 435 | $2K | |
| 87430 | <1% | 122 | $2K | |
| 82570 | <1% | 484 | $2K | |
| 82150 | <1% | 420 | $2K | |
| 87420 | <1% | 127 | $2K | |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 306 | $1K |
| 82553 | <1% | 178 | $1K | |
| 84100 | <1% | 708 | $1K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 372 | $1K |
| 36600 | <1% | 31 | $1K | |
| 80197 | <1% | 211 | $1K | |
| 84156 | <1% | 483 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 63 | $1K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 14 | $958.73 |
| 94762 | <1% | 39 | $917.12 | |
| 82607 | <1% | 113 | $887.88 | |
| 76536 | <1% | 17 | $873.32 | |
| 11045 | <1% | 382 | $811.58 | |
| 82803 | <1% | 65 | $747.65 | |
| 83540 | <1% | 175 | $710.41 | |
| 73090 | <1% | 16 | $605.03 | |
| 80143 | <1% | 74 | $566.77 | |
| 83550 | <1% | 88 | $560.79 | |
| 80179 | <1% | 74 | $539.33 | |
| 82728 | <1% | 69 | $514.15 | |
| 72170 | <1% | 13 | $491.36 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 122 | $460.60 |
| 73620 | <1% | 12 | $367.22 | |
| 85660 | <1% | 97 | $365.67 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,828 | $340.62 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,951 | $325.97 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,196 | $321.84 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 24 | $219.80 |
| 87899 | <1% | 24 | $218.03 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,693 | $185.40 |
| 84134 | <1% | 13 | $175.68 | |
| 82247 | <1% | 37 | $172.31 | |
| 80069 | <1% | 25 | $165.82 | |
| 87046 | <1% | 19 | $152.53 | |
| 87045 | <1% | 18 | $152.53 | |
| 82565 | <1% | 55 | $140.57 | |
| 85045 | <1% | 48 | $130.72 | |
| 81015 | <1% | 73 | $125.86 | |
| 84403 | <1% | 13 | $116.38 | |
| 84460 | <1% | 29 | $104.94 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,387 | $100.52 |
| 84450 | <1% | 29 | $90.22 | |
| 82465 | <1% | 31 | $89.98 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 18 | $81.67 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 268 | $81.32 |
| 82800 | <1% | 13 | $49.60 | |
| 87210 | <1% | 14 | $47.37 | |
| 82043 | <1% | 15 | $46.38 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,708 | $35.21 |
| 82270 | <1% | 18 | $28.48 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,680 | $15.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,857 | $8.89 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 15 | $6.20 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 989 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,728 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 846 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 240 | $0.00 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 97 | $0.00 |
| 77001 | 0% | 500 | $0.00 | |
| 36416 | 0% | 178 | $0.00 | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 0% | 34 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 74 | $0.00 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 0% | 130 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 15 | $0.00 |
| 96376 | 0% | 172 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 96 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 50 | $0.00 |
| C1769 | Guide wire | 0% | 18 | $0.00 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 0% | 14 | $0.00 |
| 90715 | 0% | 60 | $0.00 | |
| 84145 | 0% | 614 | $0.00 | |
| 81401 | 0% | 534 | $0.00 | |
| 76937 | 0% | 580 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 148 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 204 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 230 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 109 | $0.00 |
| C1765 | Adhesion barrier | 0% | 58 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 74 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 153 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 21 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 208 | $0.00 |
| Q9962 | High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml | 0% | 230 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 39 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 21 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 33 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 17 | $0.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 21 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOOK, KEVIN (CEO)
Parent organizationSTATE OF MISSISSIPPI-UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
| Provider | Location | Paid |
|---|---|---|
| State of Mississippi-University of Mississippi Medical Center | Grenada, MS | $2.03M |
| State of Mississippi-University of Mississippi Medical Center | Grenada, MS | $163K |
| State of Mississippi-University of Mississippi Medical Center | Grenada, MS | $39K |
| State of Mississippi-University of Mississippi Medical Center | Grenada, MS | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.